| |
| |
|
| Insider
Information: |
Coles N Anthony |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
9 |
|
| Direct
Shares |
1,005,229 |
|
|
Indirect Shares
|
124,745 |
|
|
| Direct
Value |
$36,808,775 |
|
|
|
Indirect Value
|
$4,731,561 |
|
|
| Total
Shares |
1,129,974 |
|
|
| Total
Value |
$41,540,336 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -2.1%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Vertex Pharmaceuticals Inc |
VRTX |
SVP, Comm. Ops. |
2005-02-03 |
74,540 |
2005-02-03 |
2,076 |
Premium* |
|
|
NPS Pharmaceuticals Inc |
NPSP |
President, COO & Direc... |
2008-03-17 |
220,066 |
2007-01-31 |
0 |
Premium* |
|
|
Onyx Pharmaceuticals Inc |
ONXX |
Chairman & CEO, Director |
2013-10-01 |
0 |
2008-03-31 |
0 |
Premium* |
|
|
Laboratory Corp of America |
LH |
Director |
2013-02-15 |
2,584 |
2011-01-03 |
0 |
Premium* |
|
|
Crispr Therapeutics Ag |
CRSP |
Director |
2016-10-24 |
0 |
2016-10-24 |
70,000 |
Premium* |
|
|
McKesson Corp |
MCK |
Director |
2020-08-17 |
0 |
2018-07-25 |
0 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2024-01-02 |
1,393 |
2019-01-02 |
0 |
Premium* |
|
|
Kineta Ord Shs |
KA |
Executive Chair, Direc... |
2021-02-01 |
691,008 |
2021-02-01 |
52,669 |
Premium* |
|
|
Cerevel Therapeutics Holdings, I... |
CERE |
|
2024-05-10 |
15,638 |
2022-12-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| KA |
Kineta Ord Shs |
Executive Chair |
• • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
689,890 |
689,890 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2012-08-08 |
4 |
S |
$72.18 |
$19,538,404 |
D/D |
(270,690) |
108,343 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2012-08-08 |
4 |
OE |
$29.03 |
$7,257,500 |
D/D |
250,000 |
379,033 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, COO & Director |
• • – |
2008-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
135,000 |
282,638 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2012-10-16 |
4 |
OE |
$29.03 |
$3,888,295 |
D/D |
125,599 |
233,942 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2012-10-16 |
4 |
AS |
$0.00 |
$0 |
D/D |
(125,599) |
108,343 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
Chairman & CEO |
• • – |
2013-10-01 |
4 |
D |
$125.00 |
$13,195,750 |
D/D |
(105,566) |
0 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, COO & Director |
• • – |
2008-03-14 |
4 |
A |
$0.00 |
$0 |
D/D |
76,336 |
147,638 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Director |
– • – |
2016-10-24 |
4 |
A |
$14.00 |
$980,000 |
I/I |
70,000 |
70,000 |
0 |
- |
|
| VRTX |
Vertex Pharmaceuticals In... |
SVP, Comm. Ops. |
• – – |
2004-05-06 |
4 |
A |
$0.01 |
$650 |
D/D |
65,000 |
68,840 |
|
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2011-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
114,796 |
0 |
- |
|
| NPSP |
NPS Pharmaceuticals Inc |
President, COO & Director |
• • – |
2008-03-17 |
4 |
D |
$3.85 |
$240,902 |
D/D |
(62,572) |
220,066 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-03 |
4 |
AS |
$25.43 |
$1,561,458 |
D/D |
(61,401) |
2,704 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
|
– • – |
2023-11-03 |
4 |
OE |
$3.50 |
$214,904 |
D/D |
61,401 |
64,105 |
0 |
- |
|
| ONXX |
Onyx Pharmaceuticals Inc |
President & CEO |
• • – |
2008-03-31 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
60,000 |
0 |
- |
|
| KA |
Kineta Ord Shs |
Executive Chair |
• • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
I/I |
52,669 |
52,669 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2022-12-09 |
4 |
AS |
$26.62 |
$1,333,300 |
D/D |
(50,000) |
2,704 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2022-12-09 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-02-07 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-02-07 |
4 |
AS |
$33.04 |
$1,656,401 |
D/D |
(50,000) |
2,704 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-04-11 |
4 |
AS |
$25.06 |
$1,253,130 |
D/D |
(50,000) |
2,704 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-04-11 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-05-04 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
0 |
- |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-05-04 |
4 |
AS |
$31.36 |
$1,573,434 |
D/D |
(50,000) |
2,704 |
0 |
% |
|
| CERE |
Cerevel Therapeutics Hold... |
CEO and Chairperson |
• • – |
2023-06-01 |
4 |
AS |
$32.60 |
$1,630,070 |
D/D |
(50,000) |
2,704 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
